Combination Actimid And Dexamethasone Regimen Is Promising For Relapsed And Refractory Myeloma Patients

The Journal of Clinical Oncology has reported that a combination regimen of Actimid (pomalidomide) and low-dose dexamethasone (Decadron) in a Phase 2 clinical trial was highly effective in the treatment of relapsed and refractory multiple myeloma patients.

Full article:

http://tinyurl.com/lonbyn

Regards,

Craig

Thanks craig ever the researcher....I need to be more involved but get overwhelmed by all the stuff I find. Be welll...MMS Jan

Thanks Craig~~ This confirms exactly what I thought was going to happen and I am now hoping that we will be able to have access to it in the not too distant future, simply because my Revlimid is starting to fail -- after almost 4 years, so I can't complain -- but I've been searching for the 'what next' and when I first started reading about Pomalidamide I felt that this would be the magic one for me.  Now, with your article confirming what my gut feeling was telling me, I have a stronger hope than ever!!  Thank you for keeping abreast of all of these trials -- somehow I had missed this one!!  When you hear of it being dispensed, please let us know.  Thanks once again, Cath

Say Craig, how long have you been subscribing to the Myeloma Beacon?  Do you know how long its been in operation??  We now have several top sites for Myeloma that are all running discussion and message boards -- shouldn't we be thinking about how to use them effectively?  Many thanks for bringing this site to our attention -- it looks like it keeps its finger on the pulse of what is happening across the board.  I've joined and I'm sure many others will too.

How is your wife travelling these days?  We've not heard anything in several months so I'm hoping that this means that things are going well for her.  Fingers crossed that I am right!   Cheers, Cath

Good Evening Craig;

Refreshing article! Quite inspiring.

From all that I've read and heard from my docs this stuff is  going to help us out immensely. I haven't heard a negative comment about it yet.

If any of us patients have any spare change laying around I would suggest you purchase some CELGENE  stock (tkr: CELG) becaue once this hits the market their stock is going to rocket into the ozone!

Take care;

Kevin